Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Cook Medical Treats First Patient in First-in-human Clinical Trial for Venous Valve

Cook Medical announces the first patient treated in a clinical study to evaluate a new venous valve designed for treating chronic venous insufficiency. The patient was treated by Dr. Mauricio Alviar, vascular surgeon and principal investigator, of Clinica de la Costa in Barranquilla, Colombia.

The valve’s safety and efficacy are now being tested in a global, multi-site clinical trial. The global principal investigator of the study is Dr. Paul Gagne, a vascular surgeon from Vascular Care Connecticut. In addition to being a practicing surgeon and interventionalist, Dr. Gagne brings significant experience in performing clinical trials of minimally invasive vascular medical devices.

“When leg veins function poorly, patients suffer with leg swelling, leg pain, leg ulcers, disability, and possible amputation. Therefore, it is important to restore blood flow out of the leg veins, back to the heart. Part of doing this successfully requires restoring the function of the venous valves,“ said Dr. Gagne.

In chronic venous insufficiency (CVI), a patient’s blood vessels in the lower limbs do not effectively pump blood back to the heart. The valves in the leg veins can become damaged and become less effective. CVI affects around 1 in 20 adults.[1]

To address this need, Cook Medical and Cook Advanced Technologies developed a valve that functions similar to the way the veins naturally work. The artificial valve is a novel proprietary design that mimics native venous valves.

“After extensive ultrasonic and venographic evaluation of venous anatomy, we placed the Cook Medical venous valve in the leg vein. The deployment took a few minutes and the patient had local anesthesia. It was a team effort to manage this complex case, resulting in the first clinical use of this venous valve,” said Dr. Alviar.

“First-in-human clinical trials are exciting. They are a milestone in treating patient populations with unmet needs,” said Mark Breedlove, senior vice president of Cook Medical’s Vascular division. “This first patient enrollment is a proof point of our commitment to innovation and finding unique ways to treat debilitating conditions like CVI.”

The clinical trial will continue to evaluate safety, efficacy, wound healing, leg pain and disability levels over the next five years.

To learn more about how Cook is innovating solutions for patients with venous conditions, visit

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy